|Sham intervention Wiki
|Muscular Atrophy NIH
There is one clinical trial.
While "conditioning" by exercise training has been widely evaluated, the available literature on "passive deconditioning" (i.e. forced deconditioning) is predominately limited to studies with or with almost complete mechanical and/or metabolic immobilization/sedation of the respective functional system (e.g. paralysis, bedriddenness). Vice versa, the effects of moderately long interruptions of dedicated types of exercise while maintaining everyday activity are rarely addressed. However, this topic is of high relevance, e.g. considering that breaks of health-related exercise programs due to increased family/occupational stress, vacation or temporary orthopedic limitation are rather frequent in everyday life. In the present project we aimed to determine the effects of 3 months of physical deconditioning due to COVID-19 induced lockdown after 13 month of high intensity endurance and resistance exercise in early postmenopausal women on parameters related to health and physical fitness.
Description: Body composition as determined by Dual-Energy x-Ray AbsorptiometryMeasure: Body composition Time: From intervention end to 3 months FU
Description: Hip-/Leg extension strength as determined by an isokinetic leg pressMeasure: Hip-/Leg extension strength Time: From intervention end to 3 months FU
Description: cardio-metabolic risk factors summarized in the Metabolic Syndrome Z-Score according to the definition of the International Diabetes FederationMeasure: Metabolic Syndrome Time: From intervention end to 3 months FU
Description: BMD at the lumbar spine and total hip as determined by Dual Energy x-Ray AbsorptiometryMeasure: Bone Mineral Density (BMD) Time: From intervention end to 3 months FU
Description: Menopausal symptoms as determined by the "Menopausal Rating Scale" (MRS) with a scale from 0 (no complaints) to 4 (very serious complaints).Measure: Menopausal symptoms Time: From intervention end to 3 months FU
Description: Back and joint pain as determined by a standardized pain questionnaire with a scale from 0 (never) to 7 (permanent) for pain frequency or 0 (no pain) to 7 (extremely) for pain severity.Measure: Back and joint pain Time: From intervention end to 3 months FU
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports